Gastroesophageal reflux disease (GERD): A review of conventional and alternative treatments

Alternative Medicine Review

Volumn 16, Issue 2, 2011, Pages 116-133

  Patrick, Lyn ^a  

^a BASTYR UNIVERSITY   (United States)

Author keywords

Esophagus; Gastroesophageal; GERD; Iberogast; Reflux

Indexed keywords

ACETYLSALICYLIC ACID; ALGINIC ACID; ANTACID AGENT; BILE ACID; CARBENOXOLONE; CIMETIDINE; CISAPRIDE; ESOMEPRAZOLE; FAMOTIDINE; HERBACEOUS AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; IBEROGAST; LANSOPRAZOLE; LIMONENE; LONICERA EXTRACT; MELATONIN; METOCLOPRAMIDE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PECTIN; PEPPERMINT OIL; PEPSIN A; PROKINETIC AGENT; PROTON PUMP INHIBITOR; QUERCETIN; RABEPRAZOLE; RANITIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIULCER AGENT; CURCUMIN; CYCLOHEXENE DERIVATIVE; NON PRESCRIPTION DRUG; PLANT EXTRACT; TERPENE;

ABSENCE OF SIDE EFFECTS; ACIDITY; ACUPUNCTURE; ALLERGIC ASTHMA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIOXIDANT ACTIVITY; ARTEMISIA; BILE; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DRUG INDUCED HEADACHE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS BIOPSY; ESOPHAGUS STRICTURE; FATIGUE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEART DISEASE; HELICOBACTER PYLORI; HIATUS HERNIA; HUMAN; HYPERTENSION; INSOMNIA; LIFESTYLE MODIFICATION; LONICERA; LOW CARBOHYDRATE DIET; LOWER ESOPHAGUS SPHINCTER; NAUSEA; NEURODERMATITIS; NONHUMAN; OBESITY; PANCREAS SECRETION; PATHOPHYSIOLOGY; REVIEW; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH ACID SECRETION; STOMACH EMPTYING; TARDIVE DYSKINESIA; TREMOR; MENTHA PIPERITA; METHODOLOGY; PHYTOTHERAPY;

ACUPUNCTURE THERAPY; ANTACIDS; ANTI-ULCER AGENTS; ARTEMISIA; CURCUMIN; CYCLOHEXENES; GASTROESOPHAGEAL REFLUX; HUMANS; MELATONIN; MENTHA PIPERITA; NONPRESCRIPTION DRUGS; PHYTOTHERAPY; PLANT EXTRACTS; TERPENES;

EID: 80052165665     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Vakil, N, van Zanten SV, Kahrilas p, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-1920.
2. Kahrilas PJ. Review article: gastro-oesophageal reflux disease as a functional gastrointestinal disorder. Aliment Pharmacol Ther 2004;20:50-55. (Pubitemid 39657676)
3. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710-717. (Pubitemid 40559260)
4. Sharma P, Wani S, Romero Y, et al. Racial and geographic issues in gastroesophageal reflux disease. Am J Gastroenterol 2008;103:2669-2680.
5. Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006;101:2128-2138. (Pubitemid 44337640)
6. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-146. (Pubitemid 40277094)
7. Sweet MP, Patti MG, Leard LE, et al. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg 2007;133:1078-1084. (Pubitemid 46435907)
8. Richter JE. Typical and atypical presentations of gastroesophageal reflux disease. The role of esophageal testing in diagnosis and management. Gastroenterol Clin North Am 1996;25:75-102. (Pubitemid 26093557)
9. Sontag SJ, O'Connell S, Khandelwal S, et al. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 1990;99:613-620. (Pubitemid 20243348)
10. Molina-Infante J, Ferrando-Lamana L, Mateos-Rodriguez JM, et al. Overlap of reflux and eosinophilic esophagitis in two patients requiring different therapies: a review of the literature. World J Gastroenterol 2008;14:1463-1466. (Pubitemid 351425234)
11. Spergel JM. Eosinophilic esophagitis in adults and children: evidence for a food allergy component in many patients. Curr Opin Allergy Clin Immunol 2007;7:274-278. (Pubitemid 46725772)
12. Pandolfino JE, Shi G, Curry J, et al. Esophagogastric junction distensibility: a factor contributing to sphincter incompetence. Am J Physiol Gastrointest Liver Physiol 2002;282:G1052-G1058. (Pubitemid 34651612)
13. Festi D, Scaioli E, Baldi F, et al. Body weight, lifestyle, dietary habits, and gastroesophageal reflux disease. World J Gastroenterol 2009;15:1690-1701.
14. de Vries DR, van Herwaarden MA, Smout AJ, Samsom M. Gastroesophageal pressure gradients in gastroesophageal reflux disease: relations with hiatal hernia, body mass index, and esophageal acid exposure. Am J Gastroenterol 2008;103:1349-1354. (Pubitemid 351813940)
15. Wu JC, Mui LM, Cheung CM, et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology 2007;132:883-889. (Pubitemid 46440865)
16. Lee YC, Yen AM, Tai JJ, et al. The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease. Gut 2009;58:174-178.
17. DeVault KR, Castell DO, American College of Gastorenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200. (Pubitemid 41623288)
18. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-1831. (Pubitemid 41772961)
19. Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008;57:1354-1359.
20. Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2009;30:1030-1038.
21. Boeckxstaens GE. Review article: the pathophysiology of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007;26:149-160. (Pubitemid 46985502)
22. Bredenoord AJ, Weusten BL, Curvers WL, et al. Determinants of perception of heartburn and regurgitation. Gut 2006;55:313-318. (Pubitemid 43268266)
23. Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004;99:981-988. (Pubitemid 38917796)
24. Kunsch S, Linhart T, Fensterer H, et al. Prevalence of a pathological DGER (duodeno-gastric-oesophageal reflux) in patients with clinical symptoms of reflux disease. Z Gastroenterol 2008;46:409-414. [Article in German) (Pubitemid 352016651)
25. Dvorak K, Payne CM, Chavarria M, et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 2007;56:763-771. (Pubitemid 46854189)
26. Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 1982;307:1547-1552. (Pubitemid 13245429)
27. Stephen AM, Haddad AC, Philips SF. Passage of carbohydrate into the colon. Direct measurements in humans. Gastroenterology 1983,85:589-595. (Pubitemid 13033115)
28. Piche T, Zerbib F, Varannes SB, et al. Modulation by colonic fermentation of LES function in humans. Am J Physiol Gastrointest Liver Physiol 2000;278:G578-G584. (Pubitemid 30213124)
29. Schoeman MN, Tippett MD, Akkermans LM, et al. Mechanisms of gastroesophageal reflux in ambulant healthy human subjects. Gastroenterology 1995;108:83-91.
30. Ropert A, Cherbut C, Roze C, et al. Colonic fermentation and proximal gastric tone in humans. Gastroenterology 1996;111:289-296. (Pubitemid 26256716)
31. Eriksen CA, Cullen PT, Sutton D, et al. Abnormal esophageal transit in patients with typical reflux symptoms but normal endoscopic and pH profiles. Am J Surg 1991;161:657-661.
32. Tack J. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease. Curr Opin Gastroenterol 2005;21:454-460. (Pubitemid 40961174)
33. Emerenziani S, Sifrim D. Gastroesophageal reflux and gastric emptying, revisited. Curr Gastroenterol Rep 2005;7:190-195. (Pubitemid 40916398)
34. Penagini R, Hebbard G, Horowitz M. Motor function of the proximal stomach and visceral perception in gastro-oesophageal reflux disease. Gut 1998;42:251-257. (Pubitemid 28212181)
35. Miwa H, Kondo T, Oshima T, et al. Esophageal sensation and esophageal hypersensitivity - overview from bench to bedside. J Neurogastroenterol Motil 2010;16:353-362.
36. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004;53:1024-1031. (Pubitemid 38824163)
37. Smout AJ. Review article: the measurement of non-acid gastro-oesophageal reflux. Aliment Pharmacol Ther 2007;26:7-12. (Pubitemid 350233341)
38. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006;101:1956-1963. (Pubitemid 44337616)
39. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006;55:1398-1402. (Pubitemid 44476780)
40. Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008;6:521-524.
41. Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB Jr. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 2005;50:81-85. (Pubitemid 40379144)
42. El-Serag HB. Epidemiology of nonerosive reflux disease. Digestion 2008;78:6-10.
43. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656-664. (Pubitemid 39013424)
44. Carlsson R, Frison L, Lundell L, et al. Relationship between symptoms, endoscopic findings and treatment outcome in reflux esophagitis. Gastroenterology 1996;110:A77.
45. El-Serag HB, Johanson JF. Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative patients with gastroesophageal reflux disease. Scand J Gastroenterol 2002;37:899-904. (Pubitemid 34969922)
46. Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008;103:2685-2693.
47. Quigley EM. Gastro-oesophageal reflux disease - spectrum or continuum? QJM 1997;90:75-78. (Pubitemid 27075854)
48. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 1999;94:2054-2059. (Pubitemid 29374531)
49. Bardhan KD, Royston C, Nayyar AK. Reflux rising! An essay on witnessing a disease in evolution. Dig Liver Dis 2006;38:163-168. (Pubitemid 44356161)
50. Pace F, Bianchi Porro G. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol 2004;99:946-949. (Pubitemid 39090228)
51. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006;166:965-971.
52. Bulat R, Fachnie E, Chauhan U, et al. Lack of effect of spearmint on lower oesophageal sphincter function and acid reflux in healthy volunteers. Aliment Pharmacol Ther 1999;13:805-812. (Pubitemid 29276851)
53. No authors listed. An evidence-based appraisal of reflux disease management the Genval Workshop Report. Gut 1999;44:S1-S16.
54. Pettit M. Treatment of gastroesophageal reflux disease. Pharm World Sci 2005;27:432-435. (Pubitemid 41784688)
55. Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007;(2):CD003244.
56. Vesper BJ, Altman KW, Elseth KM, et al. Gastroesophageal reflux disease (GERD): is there more to the story? ChemMedChem 2008;3:552-559.
57. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009;58:295-309.
58. Johnsson F, Hatlebakk JG, Klintenberg AC, Roman J. Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn. Scand J Gastroenterol 2003;38:347-353. (Pubitemid 36606303)
59. Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000;14:1595-1603. (Pubitemid 32011733)
60. Pohle T, Domschke W. Results of short and long-term medical treatment of gastroesophageal reflux disease (GERD). Langenbecks Arch Surg 2000;385:317-323.
61. Van Soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006;24:377-385. (Pubitemid 43972906)
62. Pollock K, Grime J. The cost and cost-effectiveness of PPIs - GP perspectives and responses to a prescribing dilemma and their implications for the development of patient-centred healthcare. Eur J Gen Pract 2003;9:126-133,140.
63. Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut 2006;55:1217-1221. (Pubitemid 44277346)
64. Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137:80-87.
65. Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999;116:239-247. (Pubitemid 29055344)
66. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric secretion. Aliment Pharmacol Ther 2005;21:149-154. (Pubitemid 40222967)
67. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther 1998;12:605-612. (Pubitemid 28327956)
68. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplicalion. N Engl J Med 1996;334:1018-1022. (Pubitemid 26123777)
69. Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000;5:206-214. (Pubitemid 34948002)
70. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-669. (Pubitemid 30171615)
71. Geboes K, Dekker W, Mulder CJ, et al. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 2001;15:1819-1826. (Pubitemid 33001146)
72. Stolte M, Meining A, Schmitz JM, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998;12:247-253. (Pubitemid 28160019)
73. Richter JE. H pylori: the bug is not all bad. Gut 2001;49:319-320. (Pubitemid 32802561)
74. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001;49:330-334. (Pubitemid 32802565)
75. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998;115:50-57. (Pubitemid 28307287)
76. Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol 1998;93:1800-1802. (Pubitemid 29071684)
77. Wu JC, Chan FK, Ching JY, et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 2004;53:174-179. (Pubitemid 38125502)
78. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:33-38. (Pubitemid 38925116)
79. Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM 2008;101:445-448. (Pubitemid 351791527)
80. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009;301:2120-2128.
81. Eurich DT, Sadowski CA, Simpson SH, et al. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med 2010;123:47-53.
82. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93-101.
83. Ip S, Bonis P, Tatstoni A, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease. Comparative Effectiveness Reviews, No 1. Rockville, MD: Agency for Healthcare Research and Quality. December 2005. www.ncbi.nlm.nih.gov/books/NBK42949/
84. Yancy WS Jr, Provenzale D, Westman EC. Improvement of gastroesophageal reflux disease after initiation of a low-carbohydrate diet: five brief case reports. Altern Ther Health Med 2001;7:120, 116-119.
85. Yudkin J, Evans E, Smith MG. The low-carbohydrate diet in the treatment of chronic dyspepsia. Proc Nutr Soc 1972;31:12A.
86. Austin GL, Thiny MT, Westman EC, et al. A very low-carbohydrate diet improves gastroesophageal reflux and its symptoms. Dig Dis Sci 2006;51:1307-1312. (Pubitemid 44315796)
87. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007;26:1333-1344. (Pubitemid 350045612)
88. Xu S, Zha H, Hou X, Chen J. Electroacupuncture accelerates solid gastric emptying in patients with functional dyspepsia. Gastroenterology 2004;126:T1163.
89. Chang X, Yan J, Yi S, et al. The affects of acupuncture at sibai and neiting acupoints on gastric peristalsis. J Tradit Chin Med 2001;21:286-288.
90. Kaada B. Successful treatment of esophageal dysmotility and Raynaud's phenomenon in systemic sclerosis and achalasia by transcutaneous nerve stimulation. Increase in plasma VIP concentration. Scand J Gastroenterol 1987;22:1137-1146. (Pubitemid 17157011)
91. Borjesson M, Pilhall M, Eliasson T, et al. Esophageal visceral pain sensitivity: effects of TENS and correlation with manometric findings. Dig Dis Sci 1998;43:1621-1628. (Pubitemid 28381564)
92. Bubenik GA, Hacker RR, Brown GM, Bartos L. Melatonin concentrations in the luminal fluid, mucosa and muscularis of the bovine and porcine gastrointestinal tract. J Pineal Res 1999;26:56-63. (Pubitemid 29113052)
93. Tan D, Manchester LC, Reiter RJ, et al. High physiological levels of melatonin in the bile of mammals. Life Sci 1999;65:2523-2529.
94. Tan DX, Manchester LC, Hardeland R, et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003;34:75-78.
95. Huether G, Poeggeller G, Reimer A, George A. Effect of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci 1992;51:945-953.
96. Bubenik GA, Pang SF, Cockshut JR, et al. Circadian variation of portal, arterial and venous blood levels of melatonin in pigs and its relationship to food intake and sleep. J Pineal Res 2000;28:9-15. (Pubitemid 30066047)
97. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, et al. Melatonin: nature's most versatile biological signal? FEBS J 2006;273:2813-2838.
98. Bubenik GA, Pang SF, Hacker RR, Smith PS. Melatonin concentrations in serum and tissues of porcine gastrointestinal tract and their relationship to the intake and passage of food. J Pineal Res 1996;21:251-256. (Pubitemid 126733143)
99. Konturek SJ, Zayachkivska O, Havryluk XO, et al. Protective influence of melatonin against acute esophageal lesions involves prostaglandins, nitric oxide, and sensory nerves. J Physiol Pharmacol 2007;58:361-377. (Pubitemid 47026568)
100. Konturek SJ, Konturek PC, Brzozowski T, Bubenik GA. Role of melatonin in upper gastrointestinal tract. J Physiol Pharmacol 2007;58:23-52.
101. Lahiri S, Singh P, Singh S, et al. Melatonin protects against experimental reflux esophagitis J Pineal Res 2009;46:207-213.
102. Pereira Rde S. Regression of gastro-esophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and amino acids: comparison with omeprazole. J Pineal Res 2006;41:195-200.
103. Kandil TS, Mousa AA, El Gendy AA, Abbas AM. The potential therapeutic effect of melatonin in gastro-esophageal reflux disease. BMC Gastroenterol 2010;10:7.
104. Ku SK, Seo BI, Park JH, et al. Effect of Lonicerae flos extracts on reflux esophagitis with antioxidant activity. World J Gastroenterol 2009;15:4799-4805.
105. Inamori M, Akiyama T, Akimoto K, et al. Early effects of peppermint oil on gastric emptying: a crossover study using a continuous real-time 13C breath test (BreathID system). J Gastroenterol 2007;42:539-542. (Pubitemid 47190070)
106. Melzer J, Rosch W, Reichling J, et al. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004;20:1279-1287. (Pubitemid 40040074)
107. Braden B, Caspary W, Borner N, et al. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil 2009;21:632-638.
108. Lambert JR, Korman MG, Nicholson L, Chan JG. In-vivo anti-reflux and raft properties of alginates. Aliment Pharmacol Ther 1990;4:615-622.
109. Waterhouse ET, Washington C, Washington N. An investigation into the efficacy of the pectin based anti-reflux formulation-Aflurax. Int J Pharm 2000;209:79-85.
110. Amdrup E, Jakobsen BM. Reflux esophagitis treated with Gaviscon. Acta Chir Scand Suppl 1969;396:16-17.
111. Chatfield S. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease. Curr Med Res Opin 1999;15:152-159. (Pubitemid 29481472)
112. Farup PG, Heibert M, Hoeg V. Alternative vs. conventional treatment given on-demand for gastroesophageal reflux disease: a randomised controlled trial. BMC Complement Altern Med 2009;9:3.
113. Young GP, Nagy GS, Myren J, et al. Treatment of reflux oesophagitis with a carbenoxolone/antacid/alginate preparation. A double-blind controlled trial. Scand J Gastroenterol 1986;21:1098-1104. (Pubitemid 17179100)
114. Reed PI, Davies WA. Controlled trial of a new dosage form of carbenoxolone (Pyrogastrone) in the treatment of reflux esophagitis. Am J Dig Dis 1978;23:161-165. (Pubitemid 8292269)
115. Markham C, Reed PI. Pyrogastrone treatment of peptic oesophagitis: analysis of 104 patients treated during a 3 1/2-year period. Scand J Gastroenterol Suppl 1980;65:73-82.
116. Maxton DG, Heald J, Whorwell PJ, Haboubi NY. Controlled trial of pyrogastrone and cimetidine in the treatment of reflux oesophagitis. Gut 1990;31:351-354. (Pubitemid 20093679)
117. Crowell PL, Elson CE, Bailey HH, et al. Human metabolism of the experimental cancer therapeutic agent d-limonene. Cancer Chemother Pharmacol 1994;35:31-37. (Pubitemid 24356744)
118. Wilkins JS Jr. Method for treating gastrointestinal disorders. U.S. Patent (6,420,435). July 16, 2002.
119. Lis-Balchin M, Ochocka RJ, Deans SG, et al. Bioactivity of the enantiomers of limonene. Med Sci Res 1996;24:309-310. (Pubitemid 26184144)
120. Lanas A, Royo Y, Ortego J, et al. Experimental esophagitis induced by acid and pepsin in rabbits mimicking human reflux esophagitis. Gastroenterology 1999;116:97-107. (Pubitemid 29013498)
121. Lanas AI, Blas JM, Ortego J, et al. Adaptation of esophageal mucosa to acid- and pepsin-induced damage: role of nitric oxide and epidermal growth factor. Dig Dis Sci 1997;42:1003-1012. (Pubitemid 27239793)
122. Orlando RC. Esophageal epithelial defenses against acid injury. Am J Gastroenterol 1994;89:S48-S52. (Pubitemid 24242359)
123. Rieder F, Biancani P, Harnett K, et al. Inflammatory mediators in gastro-esophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2010;298:G571-G581.
124. Si J, Behar J, Wands J, et al. STAT5 mediates PAF-induced NADPH oxidase NOX5-S expression in Barrett's esophageal adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2008;294:G174-G183.
125. Oh TY, Lee JS, Ahn BO, et al. Oxidative stress is more important than acid in the pathogenesis of reflux oesphagitis in rats. Gut 2001;49:364-371. (Pubitemid 32802571)
126. Rafiee P, Nelson VM, Manley S, et al. Effect of curcumin on acidic pH-induced expression of IL-6 and IL-8 in human esophageal epithelial cells (HET-1A): role of PKC, MAPKs and NF-kappaB. Am J Physiol Gastrointest Liver Physiol 2009;296:G388-G398.
127. Rao CV, Vijayakumar M. Effect of quercetin, flavonoids and alpha-tocopherol, an antioxidant vitamin, on experimental reflux oesophagitis in rats. Eur J Pharmacol 2008;589:233-238.